


COURSE PROGRAMME



Agenda

MONDAY 5 MAY 2025

08:30	Bus from hotels to Les Pensières		
9:00-9:30	Opening and Objectives of the course	Kamel Senouci , Director ADVAC, University of Geneva	Charles Mérieux conf. room
9:30-9:40	Welcome and Logistic briefing	Sandra Angèle , Director, Les Pensières, Fondation Mérieux	Charles Mérieux conf. room
SESSION 1: THE VACCINE JOURNEY: FROM VACCINES TO VACCINATION & THE IMPACT OF VACCINES			<u>Chair:</u> Adam Finn , University of Bristol
9:40-10:05	1. From Research to individual protection: The A-to-Z vaccine's journey	Arnaud Didierlaurent and Kamel Senouci , University of Geneva, Switzerland	Charles Mérieux conf. room
10:05-10:25	Discussion		
10:25-10:55	Break		
10:55-11:20	2. Vaccines Preventable Diseases' Burden and Vaccines Impact on Public Health	Kamel Senouci , University of Geneva,	Charles Mérieux conf. room
11:20-11:40	Discussion		
11:40-12:05	3. Measuring vaccination's impact in populations	Daniel Feikin , WHO, Geneva	Charles Mérieux conf. room
12:05-12:25	Discussion		
12:25-13:25	Lunch (seated, please check the tables attributed to the speakers)		Restaurant + Ogobara Doumbo
13:25-13:50	4. Where are we with vaccine-preventable diseases & immunization coverage worldwide: the state of the immunization	Kate O'Brien , WHO, Geneva	Charles Mérieux conf. room
13:50-14:10	Discussion		
14:10-14:35	5. Using vaccines to address a public health problem: the example of Polio eradication immunization strategy	Ananda Bandyopadhyay , Gates Foundation, USA	Charles Mérieux conf. room
14:35-14:55	Discussion		
14:55-15:10	Time for students to reflect personally on the learnings		
15:10-15:30	Break		
15:30-16:30	Mentoring		
16:30-18:00	Self-presentation of participants (background, interests in life...)	Social Event	Nicole Mérieux room
18:00-20:00	Welcome Reception		
20:00	Bus to hotels		

TUESDAY 6 MAY 2025

08:30 Bus from hotels to Les Pensières

SESSION 2: HOW VACCINES WORK?

Chair:
**Arnaud
Didierlaurent**,
UNIGE

09:00-09:25	6. How do vaccines protect? Immune effectors induced by vaccines: Antibodies, B and T cells, mucosal immunity	Christiane Eberhardt , University of Geneva, Switzerland	
09:25-09:45	Discussion		Charles Mérieux conf. room
09:45-10:10	7. How are vaccines' responses elicited? What a vaccinologist should know about the basic aspects of immunological responses	Arnaud Marchant , Université Libre de Bruxelles, Belgium	
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	8. How to use vaccines' platforms to tailor immune responses?	Arnaud Didierlaurent , University of Geneva, Switzerland	
11:25-11:45	Discussion		Charles Mérieux conf. room
11:45-12:10	9. Use and limitations of correlates of immunity in vaccinology	Adam Finn , University of Bristol, UK	
12:10-12:30	Discussion		
12:30-14:00	Lunch		Restaurant + O. Doumbo room
14:00-15:30	Interactive Session 1: Variability of vaccine responses in the real world Interactive session (in 2 groups + Q&A)	Christiane Eberhardt , University of Geneva, Switzerland & Arnaud Marchant , Université Libre de Bruxelles, Belgium	Charles Mérieux + Simone Mérieux
15:30-15:55	10. Immunological memory	Rafi Ahmed , Emory University, USA	
15:55-16:15	Discussion		Charles Mérieux
16:15-16:35	Time for students to reflect personally on the learnings		
16:35-16:50	Break		Restaurant
16:50-18:30	Soccer, Mōlky, Pétanque...	Social Event	Outside
18:30-19:00	Aperitive		Nicole Mérieux + Restaurant / Ogobara Doumbo
19:00-20:30	Dinner		
20:30	Bus to hotels		

WEDNESDAY 7 MAY 2025

08:30 Bus from hotels to Les Pensières

SESSION 3 – VACCINE TECHNOLOGY & MANUFACTURING (PART ½)

Chair: **Emily Erbeling**,
Director, DMID,
NIH, USA

09:00-09:25	11. Landscape in vaccine and immunization technologies	Cristina Casetti , Independent Expert, USA	
09:25-09:45	Discussion		Charles Mérieux conf. Room
09:45 -10:10	12. Vaccine market, market shaping and regional initiatives for vaccine production	Tania Cernuschi , WHO, Switzerland	
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	13. Concepts of Chemistry, Manufacturing, and Controls (CMC) for vaccines	Ozzie Berger , Hillevax, USA	
11:25-11:45	Discussion		
11:45-12:10	14. The complexity of quality control in vaccine manufacturing	Philippe Juvin , Sanofi Pasteur, France	Charles Mérieux
12:10-12:30	Discussion		
12:30-12:45	Time for students to reflect personally on the learnings		
12:45-14:00	Lunch		Restaurant + Ogobara Doumbo

SESSION 4 – VACCINE REGULATORY

Chair: **Emily Erbeling**,
Director, DMID,
NIH, USA

14:00-14:25	15. The role of Regulatory Agencies	Marco Cavaleri , EMA, The Netherlands	Charles Mérieux
14:25-14:45	Discussion		
14:45-16:30	Small Group Exercise 1: Vaccine Regulatory 4 Groups: <ul style="list-style-type: none"> ○ 1. Ozzie Berger & Norman Baylor ○ 2. Arnaud Didierlaurent & Donna Boyce ○ 3. Olga Rovira & Luis Jodar ○ 4. Marco Cavaleri & Veronica Gambillara-Fonck 	Norman Baylor , Biologics Consulting Group, USA, Ozzie Berger , Hillevax USA, Donna Boyce , Pfizer USA, Marco Cavaleri , EMA, Netherland, Arnaud Didierlaurent , UNIGE, Switzerland, Veronica Gambillara-Fonck , Pureos Bioventures, Switzerland, Luis Jodar , Pfizer, USA, Olga Rovira , Kontivax, Belgium.	Charles Mérieux + Ogobara Doumbo + Simone Mérieux + Nicole Mérieux
16:30-17:00	Break		Restaurant
17:00-18:30	Interactive Session 2: Optional lecture from Industry	DCVMN and IFPMA members	Charles Mérieux + Simone Mérieux

Special lecture: THE 9th LAMBERT LECTURE

18:30-18:35	Introduction	Paul-Henri Lambert	
18:35-19:00	16. The future of health	Andrew Pollard , University of Oxford, UK	Charles Mérieux
19:00-19:20	Discussion		
19:30	Dinner		Restaurant + O. Doumbo
21:00	Bus to hotels		

THURSDAY 8 MAY 2025

08:30 Bus from hotels to Les Pensières

SESSION 3 – VACCINE TECHNOLOGY & MANUFACTURING (PART 2/2)

Chair: **Emily Erbeling**, DMID, NIH, USA

09:00-09:25 **17. Delivering a pandemic vaccine in 100 Days: What does it take?** **Jakob Cramer**, CEPI, UK

09:25-09:45 Discussion

09:45-10:45 **Interactive session 3 - Q&A**

Everything you always wanted to know on what makes funders support research-development: ask all your questions to governmental agencies, venture capitalists, industry and philanthropic organizations.

Panelists:

Connie Cai, Gates Foundation, USA, **Jakob Cramer**, CEPI, UK, **Emily Erbeling**, Independent Expert, USA, **Veronica Gambillara**, Pureos Bioventures, Switzerland, **Luis Jodar**, Pfizer, USA.

Charles Mérieux Conf room

10:45-11:00 Break

Restaurant

SESSION 5 – ASSESSING VACCINES IN CLINICAL TRIALS (Part 1/2)

Chair: **Edwin Asturias**, Children's Hospital Colorado, USA

11:00-11:25 **18. Clinical trials: an overview of issues to be considered** **Kathy Neuzil**, Independent expert, USA

11:25-11:45 Discussion

Charles Mérieux

11:45-12:10 **19. Introduction to statistical aspects of clinical trials** **Martha Nason**, PATH, USA

12:10-12:30 Discussion

12:10-12:45 *Working lunch:*

Participants eat at the Restaurant with their group and go back to their room for the SGE 2

Restaurant + Terrasse

12:45-15:00 **Small Group Exercise 2:**

How to design, recruit volunteers for, and analyze the results of selected phase II trials

7 Groups:

Group 1: S. Aureus: V. Gambillara & B. Gessner
Group 2: Ebola: M. Nason & H. Whitaker
Group 3: Dengue: N. Baylor & A. Durbin
Group 4: RSV: E. Asturias & K. Talaat
Group 5: Mpox: K. Johansen
Group 6: Typhoid conjugate vaccines: K. Senouci
Group 7: Coronavirus: E. Erbeling

Check Group assignment and rooms on boards

15:00-15:25 **20. Assessing herd protection and vaccine effectiveness (and use for licensure)** **John Clemens**, International Vaccine Institute (IVI), Republic of Korea

15:25-15:45 Discussion

Charles Mérieux

15:45-16:10 **21. Clinical trials: role of a Data Safety Monitoring Board (DSMB)** **Robert Heyderman**, University College London, UK (via Zoom)

16:10-16:30 Discussion

16:30-16:50 Break

Restaurant

16:50-17:15 **22. Human Challenge Trials** **Chris Chiu**, Imperial College London, UK

17:15-17:35 Discussion

Charles Mérieux

17:35-17:50 Time for students to reflect personally on the learnings

18:00-19:30 Dinner

Restaurant + O.Doumbo

19:30 Bus to hotels

FRIDAY 9 MAY 2025

08:30 Bus from hotels to Les Pensières

SESSION 6 – VACCINE SAFETY - ASSESSMENT OF ADVERSE EFFECTS

Chair: Kari Johansen, Public Health Agency, Sweden

09:00-09:25	23. How do vaccines cause adverse events? (Including Immune-mediated diseases)	Kawsar Talaat , Johns Hopkins Bloomberg School of Public Health, USA	
09:25-09:45	Discussion		Charles Mérieux Conf room
09:45-10:10	24. WHO Guidance on how to detect and manage safety issues	Madhav Balakrishnan , WHO, Switzerland	
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	25. Population-based post-licensure surveillance (including study methodology for signal validation and epi studies)	Heather Whitaker , UKHSA, UK	
11:25-11:45	Discussion		Charles Mérieux
11:45-12:10	26. Immunization safety in low- and middle-income country vaccination programs	Kamel Senouci , University of Geneva	
12:10-12:30	Discussion		
12:30-14:00	Lunch		Restaurant + Ogobara Doumbo

SESSION 5 – ASSESSING VACCINES IN CLINICAL TRIALS (Part 2/2)

14:00-14:30	Mentoring		
14:30-16:40	Small group exercise 3: Vaccine trial Phase III planning, implementation, analysis of the study results	7 Groups: Group 1: V. Gambillara & B. Gessner Group 2: M. Nason & H. Whitaker Group 3: N. Baylor & A. Durbin Group 4: E. Asturias & K. Talaat Group 5: K. Johansen Group 6: K. Senouci Group 7: E. Erbeling	Charles Mérieux O.Doumbo Nicole Mérieux Simone Mérieux Mandallaz Chavoires Salon du Dr
16:40-16:55	Break		Restaurant
16:55-17:10	Time for students to reflect personally on the learnings		

Special lecture: THE 17TH PLOTKIN LECTURE

17:10-17:15	Introduction	Edwin Asturias , Children's Hospital Colorado, USA	
17:15-17:40	27. Multiple Antigen Presenting System Vaccines (MAPS)	Rick Malley , Boston Children's Hospital, USA	Charles Mérieux
17:40-18:00	Discussion		
18:00-20:00	Reception Dinner		Restaurant + Ogobara Doumbo
20:00	Bus to hotels		

SATURDAY 10 MAY 2025

08:30 Bus from hotels to Les Pensières

SESSION 7 - ETHICAL ISSUES

Chair: **Kari Johansen**,
Public Health
Agency,
Sweden

09:00-09:25 **28. Applied ethics in immunization programs and practice** **Anuradha Rose**, Christian Medical College of Vellore, India

09:25-09:45 Discussion

Charles
Mérieux
conf room

09:45-10:10 **29. Principles, guidelines and frameworks for ethical considerations in clinical trials of vaccines** **Catherine Slack**, University of KwaZulu-Natal, South Africa

10:10-10:30 Discussion

10:30-10:50 Break

Restaurant

10:50-13:00 **Small group exercise 4:**

Facilitators (7 Groups):

Ethical considerations in vaccine trials

Edwin Asturias, Kari Johansen, Anuradha Rose, Kamel Senouci, Catherine Slack, Martha Nason, Kawsar Talaat.

Charles Mérieux
O.Doumbo
Nicole Mérieux
Simone Mérieux
Mandallaz
Chavoires
Salon du Dr

13:00-13:10 Time for students to reflect personally on the learnings of the morning

13:10-14:00 Sandwiches Buffet

Take away or
eat at the
Restaurant

14:00 Bus to Hotels and Free time in the afternoon

18:45 Bus from Hotels to Les Pensières

19:00 Dinner upon Registration

Restaurant

20:30 Bus from Les Pensières to hotels

SUNDAY 11 MAY 2025

18:45 Bus from hotels to Les Pensières (for dinner only)

19:00 Dinner upon registration

Restaurant

20:30 Bus from Les Pensières to hotels

MONDAY 12 MAY 2025

08:30	Bus from hotels to Les Pensières		
09:00-09:10	Ethical considerations in vaccine trials: Recap	Catherine Slack , University of KwaZulu-Natal, South Africa	Charles Mérieux conf. Room
SESSION 8 – DECISION MAKING FOR VACCINES (Part 1/2)			Chair: Kamel Senouci , UNIGE
09:10-09:35	30. The decision-making processes for vaccines use: global, regional and local perspectives	Rudzani Muloiwa , University of Cape Town, South Africa	
09:35-09:55	Discussion		Charles Mérieux
09:55-10:20	31. The decision-making processes for vaccines' use: what should experts consider	Kari Johansen , Public Health Agency of Sweden	
10:20-10:40	Discussion		
10:40-11:10	Break		Restaurant
11:10-11:35	32. The example of the WHO SAGE decision making processes	Joachim Hombach , WHO Geneva, Switzerland	
11:35-11:55	Discussion		Charles Mérieux
11:55-12:20	33. The role of health economics (including modelling) as a tool in analyzing vaccine policy options	Marc Brisson , Université de Laval, Canada	
12:20-12:40	Discussion		
12:40-13:40	Lunch		Restaurant + Winter Garden
13:40-15:50	Small group exercise 5 Decision-making for the evaluation and impact assessment of new vaccines introduced in selected countries: safety and effectiveness.	7 Groups: <ul style="list-style-type: none"> • Group 1: Rotavirus: K. Talaat • Group 2: HPV: K. Senouci • Group 3: Dengue LMICs: B. Gessner & H. Nohynek • Group 4: Zoster: K. Johansen • Group 5: Malaria: K. Neuzil • Group 6: RSV Adults: K. Talbot • Group 7: RSV: J. Englund 	Charles Mérieux + O. Doumbo + Simone Mérieux + Nicole Mérieux + Chavoires + Mandallaz + Salon du Dr
15:50-16:20	Break		Restaurant
SESSION 9 – UPDATES ON VACCINES (part 1/4)			Chair: Anna Durbin , Johns Hopkins School of Public Health, USA
16:20-16:45	34. Polysaccharide and conjugate vaccines	David Goldblatt , University College London, UK	
16:45-17:05	Discussion		Charles Mérieux conf. Room
17:05-17:30	35. Pneumococcal conjugate vaccines: the impact of PCV, its introduction in different populations (including adults & children) and the change in PCV valency stereotypes	Keith Klugman , Gates Foundation, USA	
17:30-17:50	Discussion		
17:50-18:35	Mentoring		Check boards for group assignments
18:35-18:50	Time for students to reflect personally on the learnings		
19:00-20:30	Dinner		Restaurant + O. Doumbo
20:30	Bus to hotels		

TUESDAY 13 MAY 2025

08:30 Bus from hotels to Les Pensières

SESSION 9 – UPDATES ON VACCINES (part 2/4)

Chair: Anna Durbin, Johns Hopkins School of Public Health, USA

09:00-09:25	36. HPV vaccines	Margaret Stanley , Cambridge University, UK (via Zoom)	
09:25-09:45	Discussion		Charles Mérieux conf. Room
09:45-10:10	37. Typhoid vaccines	Kathy Neuzil , NIH Fogarty, USA	
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	38. Meningococcal vaccines	Shamez Ladhani , UKHSA, UK	
11:25-11:45	Discussion		
11:45-12:10	39. Vaccines against arboviruses (Dengue, Zika, Chikungunya)	Anna Durbin , Johns Hopkins Bloomberg School of Public Health, USA	Charles Mérieux
12:10-12:30	Discussion		
12:30-12:40	Time for students to reflect personally on the learnings		
12:40-14:10	Lunch		Restaurant + O. Doumbo
14:10-14:35	40. Rotavirus and norovirus vaccines	Umesh Parashar , Centers for Disease Control, Atlanta, USA (via Zoom)	
14:35-14:55	Discussion		
14:55-15:20	41. Flu vaccines	Kanta Subbarao , Université de Laval, Canada	Charles Mérieux
15:20-15:40	Discussion		
15:40-16:05	42. COVID vaccines	Hanna Nohynek , Finnish Institute for Health and Welfare, Finland	
16:05- 16:25	Discussion		
16:25-16:55	Break		Restaurant

SESSION 8 – DECISION MAKING FOR VACCINES (Part 2/2)

16:55-18:05	Small group exercise 6 Sharing recommendations with the Authorities on the impact on the immunization program.	Restitution of the 7 Groups from Exercise 5	Charles Mérieux room
18:05-18:20	Time for students to reflect personally on the learnings		
18:30-20:00	Dinner		Restaurant + Ogobara Doumbo room
20:00	Bus to hotels		

WEDNESDAY 14 MAY 2025

08:30 Bus from Hotels to les Pensières

SESSION 10 - SELECTING APPROPRIATE VACCINATION STRATEGIES

Chair: Hanna Nohynek,
Finnish
Institute for
Health and
Welfare,
Finland

09:00-09:25	43. RSV	Janet Englund, University of Washington/Seattle Children's Hospital Seattle, USA	
09:25-09:45	Discussion		Charles Mérieux
09:45-10:10	44. Vaccination and pregnancy and early life	Christiane Eberhardt, University of Geneva, Switzerland (via Zoom)	conf. Room
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	45. Vaccination schedules: Past, present and future - is there some rationale?	Edwin Asturias, Children's Hospital Colorado, USA	
11:25-11:45	Discussion		
11:45-12:10	46. Vaccine responses and efficacy in the elderly	Keipp Talbot, Vanderbilt University, USA	Charles Mérieux
12:10-12:30	Discussion		
12:30-12:55	47. Vaccination in immuno-compromised individuals	Christoph Berger, University of Basel, Switzerland	
12:55-13:15	Discussion		
13:15-14:45	Lunch		Restaurant + Winter Garden

14:45-16:25 PARALLEL SESSIONS (rotation of two 45 min-Sessions)			
	1. National decision-making for immunization programmes	Christoph Steffen WHO Geneva & Louise Henaff, WHO Geneva	Charles Mérieux
	2. Clinical vaccinology: patients' problem solving	Alessandro Diana, University Hospitals of Geneva (HUG)	Salon du Dr
	3. New approaches towards vaccination e-registries	Julia Stowe, UKHSA, UK, Carolina Danovaro, WHO Geneva, and Kari Johansen, Public Health Agency, Sweden	Simone Mérieux
	4. Cold Chain management	Souleymane Kone, WHO Geneva	Mandallaz
	5. Monitoring immunization program performance	Jan Grevendonk & Laure Dumolard, WHO Geneva	Nicole Mérieux
	6. AEFI causality assessment	Madhav Balakrishnan, WHO, Geneva	O. Doumbo or Chavoires
16:25-16:45	Break		Restaurant

SESSION 9 – UPDATES ON VACCINES (Part 3/4)

Chair: Edwin Asturias,
Children's
Hospital
Colorado,
USA

16:45-17:10	48. Cholera vaccines	Alejandro Cravioto, National Autonomous University of Mexico	Charles Mérieux
17:10-17:30	Discussion		conf. Room
18:00-19:30	Dinner upon registration		Restaurant
19:30	Bus to hotels		

THURSDAY 15 MAY 2025

08:30 Bus from hotels to Les Pensières

SESSION 9 – UPDATES ON VACCINES (Part 4/4)

Chair: Edwin Asturias,
Children's Hospital Colorado, USA

09:00-09:25	49. Non-specific effects of vaccines	Nigel Curtis, The Royal Children's Hospital, Melbourne, Australia	
09:25-09:45	Discussion		Charles Mérieux conf. Room
09:45-10:10	50. Malaria vaccines	Mary Hamel, WHO, Geneva	
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	51. Tuberculosis vaccines	Helen McShane, University of Oxford, UK	Charles Mérieux
11:25-11:45	Discussion		

SESSION 11 – REACHING SPECIFIC GROUPS

Chair: Kamel Senouci,
University of Geneva

11:45-12:10	52. How to better reach the zero-dose or under-vaccinated children in LMICs	Narendra Arora, INCLIN, India	
12:10-12:30	Discussion		Charles Mérieux
12:30-12:55	53. Life-course vaccines: how to better reach individuals from childhood to elderly?	Pierre Vandamme, University of Antwerp, Belgium	
12:55-13:15	Discussion		
13:15-14:15	Lunch		Restaurant + Ogobara Doumbo room
14:15-14:40	54. The determinants of vaccine acceptance	Eve Dubé, Université de Laval, Canada	
14:40-15:00	Discussion		
15:00-16:00	Interactive session 4 How to address vaccine hesitancy at individual and community levels? Q&A	Steve Lewandowsky, Bristol University Eve Dubé, Université de Laval Naveen Thacker, International Pediatric Association Alejandro Cravioto, National Autonomous University of Mexico, Noni McDonald, Dalhousie University	Charles Mérieux
16:00-16:20	Break		Restaurant

Special Session: 25 YEARS OF ADVAC

Opening by Antoine

16:20-18:00	25 years of ADVAC, what impact and what future? Panel (Panelists and Alumni) Panelists: Paul-Henri Lambert, Alain Mérieux, Stanley Plotkin, Alumni: Edwin Asturias (University of Colorado, USA), Benjamin Kagina (University of Cape Town, South Africa), Helen Matzger (Gates Foundation, USA), Naveen Thacker (IPA, India) Jennifer Moïsi (Pfizer, France) ...		Charles Mérieux
18:00	Bus departure from les Pensières to hotels (check board for return bus from hotels to the Menthon Castle)		
18:45	Bus departure from Catalpa Hotel to Les Pensières		Meet at the Reception Lobby
19:00	Bus departure from Les Pensières to Château de Menthon Saint Bernard for visit of the castle and the ADVAC 25 Gala Dinner		
22:30 and 23:45	Buses from Château de Menthon to les Pensières & hotels		

FRIDAY 16 MAY 2025

08:30 Bus from hotels to Les Pensières

SESSION 12: FACING THE MEDIA: WHAT THE VACCINOLOGIST SHOULD KNOW IN THE CONTEXT OF VACCINE HESITANCY AND ANTI-IMMUNIZATION LOBBY

Chair: **Kamel Senouci**,
UNIGE

09:00-11:00	Interactive session 5 Introduction to media dynamics: How to best deliver vaccinology-related messages to different interest groups	Deborah Hall , Broadcaster and Media Affairs Consultant, London, UK	Dr. Charles Mérieux conf. Room
11:00-11:20	Break		Restaurant
11:20-13:20	Introduction to media dynamics: How to best deliver vaccinology-related messages to different interest groups (continued)	Deborah Hall , Broadcaster and Media Affairs Consultant, London, UK	Charles Mérieux
13:20-14:20	Lunch		Restaurant + O. Doumbo

SESSION 13: CLOSING

14:20-14:50	Time for participants to complete the final evaluation		Charles Mérieux
14:50-15:50	Diploma ceremony, awarding of CME credits and closure of the course	Kamel Senouci , Director, ADVAC, University of Geneva	
16:00	Bus from Les Pensières to hotels (check boards for Schedule)		
18:00-19:30	Dinner upon registration (transportation to be confirmed)		Restaurant

WEDNESDAY 7 MAY 2025

SESSION 3: VACCINE TECHNOLOGY, MANUFACTURING AND APPROVAL

Chair: Kamel Senouci,
Director
ADVAC,
University of
Geneva

17:00-18:30 **Interactive Session 2**

From ideas to implementation - the realities of funding for vaccine research and development in the private sector

Two 45-minutes sessions (2 groups switching)

Group A: starting with Rajinder Suri and Ricardo Godoï

Group B: starting with Luis Jodar

Luis Jodar, Pfizer, USA &
Rajinder Suri, DCVMN & **Ricardo de Mattos Godoï Ferreira**, Bio-Manguinhos Fiocruz

Room
Charles
Mérieux
(Luis Jodar)
+
Room Nicole
Mérieux
(Rajinder Suri
+ Ricardo
Godoï)

DRAFT